Establishment and characterization of a novel cell line derived from dedifferentiated liposarcoma patients, NCC-DDLPS6-C1

This article was originally published here

Hum cell. 2022 May 23. doi: 10.1007/s13577-022-00710-8. Online ahead of print.


Dedifferentiated liposarcoma (DDLPS) is morphologically characterized by well-differentiated liposarcomas associated with a high-grade non-lipogenic sarcoma and characterized molecularly by the coamplification of MDM2 and CDK4(12q14-15). DDLPS is very aggressive and effective systemic chemotherapy has not yet been developed. In this study, we established a novel DDLPS cell line, NCC-DDLPS6-C1, as a potential tool for the development of novel therapies. NCC-DDLPS6-C1 cells were established from surgically resected tumor tissue from a patient with DDLPS. Amplification and overexpression of MDM2 and CDK4 were observed in NCC-DDLPS6-C1 cells. NCC-DDLPS6-C1 cells proliferated rapidly, invaded aggressively, and formed spheroids. Additionally, NCC-DDLPS6-C1 cells formed tumors in mice. These observations suggest that malignant potentials that may reflect the original features of DDLPS have been retained in NCC-DDLPS6-C1. Anticancer drugs that significantly reduced NCC-DDLPS6-C1 cell proliferation were identified by drug library screening. Thus, NCC-DDLPS6-C1 can recapitulate the original genotypes and phenotypes, and we conclude that the NCC-DDLPS6-C1 cell line is a useful resource for the study of DDLPS.

PMID:35604485 | DOI:10.1007/s13577-022-00710-8

Comments are closed.